Welcome to our dedicated page for Scorpius Holdings news (Ticker: $NHWK), a resource for investors and traders seeking the latest updates and insights on Scorpius Holdings stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Scorpius Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Scorpius Holdings's position in the market.
Rhea-AI Summary
Scorpius Holdings, Inc (NYSE American: SCPX) secures a $1 million contract with an NIH-funded researcher for therapeutic antibody development. The company will optimize and manufacture the antibody for preclinical studies, with potential expansion to Phase 1 clinical manufacturing. CEO Jeff Wolf emphasizes the company's unique capabilities and commitment to academic partnerships.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.63%
Tags
-
Rhea-AI Summary
Scorpius Holdings, Inc (SCPX) joins the BioMaP-Consortium, providing access to $20 billion funding and streamlined government project access. The partnership aims to enhance biomanufacturing capabilities for medical countermeasures to combat public health threats.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.46%
Tags
-
Rhea-AI Summary
Scorpius Holdings, Inc. (NYSE American: SCPX) closes public offering of 10,000,000 shares of common stock, generating $1,500,000 in gross proceeds. The funds will be used for working capital and general corporate purposes. ThinkEquity served as the book-running manager for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.13%
Tags
Rhea-AI Summary
Scorpius Holdings, Inc. (NYSE American: SCPX) announced the pricing of a public offering of 10,000,000 shares of common stock at $0.15 per share, generating $1,500,000 in gross proceeds. The offering is expected to close on March 12, 2024, with net proceeds intended for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-51.47%
Tags
-
Rhea-AI Summary
Scorpius Holdings, Inc. (NYSE American: SCPX) plans to offer shares of common stock in a public offering managed by ThinkEquity for working capital and corporate purposes. The offering is made under a shelf registration statement on Form S-3 with the SEC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-51.47%
Tags
-
Rhea-AI Summary
Scorpius Holdings, Inc. reports a significant reduction in operating loss and a record backlog for the fourth quarter of 2023. The company estimates a sequential increase in revenue of over 375% compared to the previous quarter, with a strong pipeline of new opportunities for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.59%
Tags
Rhea-AI Summary
NightHawk Biosciences / Scorpius Holdings, Inc. (NHWK; SCPX) has completed a name change to better reflect its shift into a pure-play, large molecule biomanufacturing CDMO. The name and ticker symbol changes do not affect the share structure or rights of the shareholders. The CEO, Jeff Wolf, highlighted the company's evolution into a revenue-generating biomanufacturing company and expansion of CDMO services, aiming to fill the critical void in the biopharmaceutical sector.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.71%
Tags
-
Rhea-AI Summary
NightHawk Biosciences (NHWK) announces the promotion of Joe Payne to President and COO of Scorpius BioManufacturing. Payne brings over 20 years of experience in biopharma and pharmaceuticals and has held leadership roles at CDMOs Tergus Pharma and Alcami Corporation. He will oversee quality, manufacturing, process sciences, and commercial operations. CEO Jeff Wolf expressed confidence in Payne's abilities, emphasizing his expertise in developing and implementing quality production processes. Payne will focus on building a robust quality operation and working with clients to bring biologic innovations to patients efficiently and safely.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
NightHawk Biosciences, a CDMO, announced the sale of non-core IP, receiving $2.25 million from a note. The note bears interest at 1% and may be convertible into shares of NightHawk's common stock at an 8% premium. The CEO stated that the funds strengthen the balance sheet and provide additional working capital. The sale of IP aligns with the strategy to focus on Scorpius BioManufacturing subsidiary. NightHawk Biosciences, through Scorpius, offers CDMO services for biologic and cell therapy programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.7%
Tags
Rhea-AI Summary
NightHawk Biosciences (NHWK) announced its Scorpius BioManufacturing subsidiary has been awarded a multimillion-dollar contract to provide process development, analytical, and cGMP manufacturing services for a biotech company’s Phase 2 clinical program. The CEO expressed pride in being selected to help advance this potentially lifesaving therapy and highlighted Scorpius' adaptability, dedicated service, and commitment to meeting project timelines. The scope of work is expected to be completed in 2024, and the company is excited to see the momentum continue as demand for its biomanufacturing services rises.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.76%
Tags
Scorpius Holdings, Inc.
NYSE:NHWK
NHWK Rankings
NHWK Stock Data
14.90M
24.16M
7.33%
8.61%
1.18%
Pharmaceutical Preparation Manufacturing
Manufacturing
US
Morrisville
About NHWK
heat biologics is a clinical-stage company focused on developing its proprietary impact™ (immune pan-antigen cytotoxic therapy), a fully allogeneic (“off-the-shelf”) cell-based immunotherapy for use in the treatment of a wide range of cancers. heat's impact therapy is a first-in-class, fully human immunotherapy that functions as both an immune stimulator and an antigen-delivery system. impact effectively transforms living allogeneic cells into "osmotic pumps" that continuously secrete cancerous antigens to robustly stimulate the immune system against the targeted cancer. impact therapy is applicable to a wide range of cancers. heat is currently conducting two phase 2 clinical trials with its hs-110 to treat non-small cell lung cancer (nsclc) and its hs-410 to treat bladder cancer.